- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00857688
Efficacy of the Combination Bismuth + Neomycin + Procaine in the Treatment of Recurrent Aphthous Ulceration
Randomized Clinical Study to Evaluate the Effectiveness and Safety of the Drug Topic Bismu-Jet ® (Bismuth Tartrate, Neomycin Sulphate and Procaine Hydrochloride) Compared to Placebo in Improvement of Signs and Symptoms of Ulcerations Caused Disease.
Study Overview
Detailed Description
The period of practical study will be conducted at the Center for Orofacial Rehabilitation Aesthetics, located in Campinas-SP, where there are several beds and a large number of people served by dentists attending post-graduate, under the supervision of Dr. Claudio Azenha. Thus, patients are instructed to find the center if they experience the first signs of UARs.
Will be included only where the top of the table has not extrapolated 48 hours. These patients will be referred to the visit of screening and early treatment (day 0 - Visit 01). At a screening visit will be informed all the relevant aspects of research, enabling the patient judge the feasibility of their participation in the study. After signing the Informed Consent, patients will be randomized and will receive one of the treatments. This consultation will be a clinical examination where the examiner will tell the lesions and measure the size of each. Besides the clinical examination there is a subjective test, in which the patient must consider the intensity of pain you're feeling at that moment, using the visual analogue scale (VAS). The drug will be administered by the investigator, the patient showing the correct way of administration. After 15 minutes, the pain will be measured again, using the VAS.
After three days, patients should return for the 02 tour, which will be clinically evaluated and will be assessed for intensity of pain, in addition to the reporting of adverse events. The same procedures will be repeated in the return of seven days (Visit 03). This visit some patients may receive high clinic.
The study will be finalized after 14 days of treatment (Visit 04), when patients must return to the office to the final evaluations, as will high or be exempted from the clinical study.
Patients who do not have improvement in time, receive replacement therapy funded by the sponsor and provided by waxen, according to the needs of each individual case, judged by expert researchers.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
SP
-
Valinhos, SP, Brazil, 13270000
- LAL Clínica Pesquisa e Desenvolvimento Ltda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Consistency with the purposes of the study and all topics of FICT;
- Age above 12 years;
- Both sexes;
- Diagnosis of type UAR minor
Exclusion Criteria:
- Use of nutritional supplements such as iron, folic acid and vitamins of the B complex;
- immunocompromised;
- systemic diseases (endocrine-metabolic);
- rheumatic diseases;
- Pregnancy and lactation;
- Use of topical or systemic corticosteroids;
- UAR type major;
- UAR type Herpetiformis;
- UAR over 48 hours of development;
- Background allergic to any components of the formula.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1 - Test
Patients will recieve the association.
|
Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
|
PLACEBO_COMPARATOR: 2
Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
|
Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The pain will be assessed by visual analogue scale. Will evaluate the size of the lesion using a ruler created specifically for this study The number of lesions will be evaluated by counting.
Time Frame: V0 - 1st day, V1 - 3st day, V2 - 7th day, V3 - 14th day
|
V0 - 1st day, V1 - 3st day, V2 - 7th day, V3 - 14th day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety will be assessed by the incidence of adverse reactions
Time Frame: V0 - 1st day, V1 - 3st day, V2 - 7th day, V3 - 14th day
|
V0 - 1st day, V1 - 3st day, V2 - 7th day, V3 - 14th day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BNPEMS0209
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aphtous Ulcers
-
University Hospital, RouenNot yet recruiting
-
University of CreteCompletedIschemic Foot Ulcers
-
Azidus BrasilSuspended
-
Medical University of South CarolinaCompletedVenous Ulcers | Leg Ulcers | Varicose UlcersUnited States
-
Nordsjaellands HospitalSkane University Hospital; ReapplixCompletedDiabetic Malleoli Ulcers | Malleoli UlcersDenmark, Sweden
-
Lohmann & RauscherCompletedSurgical Wound | Venous Leg Ulcer | Pressure Ulcer | Skin Graft | Arterial Ulcers | Diabetic UlcersPoland
-
Oneness Biotech Co., Ltd.Taipei Veterans General Hospital, Taiwan; Taipei Medical University Shuang...RecruitingVenous Leg Ulcers (VLU)Taiwan
-
Molnlycke Health Care ABCompletedVenous Leg Ulcers | Mixed Leg UlcersFrance, Germany, Netherlands, Czech Republic
-
Skingenix, Inc.Completed
-
University of TurkuUnknown
Clinical Trials on Bismu-Jet
-
Rambam Health Care CampusUnknown
-
RenJi HospitalShanghai Tongji Hospital, Tongji University School of Medicine; Shanghai Pudong...UnknownHypoxia | Gastric Cancer | Peptic Ulcer | Esophagus Cancer | OesophagitisChina
-
Taysha Gene Therapies, Inc.National Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingGene Transfer | Giant Axonal NeuropathyUnited States
-
Centre hospitalier de l'Université de Montréal...Ozmosis Research Inc.; Quebec Breast Cancer Foundation; Ministère de l'Économie...Not yet recruiting
-
Erasme University HospitalNot yet recruitingBronchoscopy | High-Frequency Jet VentilationBelgium
-
Damascus UniversityCompletedPlaque, DentalSyrian Arab Republic
-
Polyclinic of the Hospitaller Brothers of St. John...Terminated
-
Al-Azhar UniversityActive, not recruitingClass II Division 1 MalocclusionEgypt
-
Eye & ENT Hospital of Fudan UniversityUnknownOther Complications of Surgical and Medical ProceduresChina
-
PharmaJet, Inc.CompletedInfluenza ProphylaxisUnited States